Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,425.50
(
0.13%
)
News Focus
News Focus
Post# of 257300
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Monday, 04/11/2005 12:34:18 AM

Monday, April 11, 2005 12:34:18 AM

Post# of 257300
DNDN to present interim 9902a survival data at ASCO

Oral presentation on Sunday, May 15, 2005 (scan to the second item from bottom):

http://www.asco.org/ac/1,1003,_12-002556-00_18-008954,00.asp

>>
Presenter: Celestia S. Higano, MD

Immunotherapy (APC8015) for androgen independent prostate cancer (AIPC): Progression and interim survival from a second phase III trial. Abstract No: LBA4519
<<

[Thanks to ‘radiationcancerdoc’ for this find]

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today